Cabiralizumab in Phase II for pancreatic cancer, Five Prime receives $25M milestone

Bristol-Myers Squibb Co. (NYSE:BMY) began a Phase II trial to evaluate cabiralizumab (FPA008) plus Opdivo nivolumab with and without chemotherapy in

Read the full 213 word article

User Sign In